


UK CAA Oncology Certification Charts

1. Colorectal
2. Malignant melanoma
3. Germ cell tumour of testis
4. Renal cell carcinoma
5. Breast carcinoma – under review
6. Non-small cell lung cancer


Note: All Class 1 cases shall be referred to the AMS.

Certification assessment following colorectal cancer




Dukes' stage A = T₁₋₂

Dukes' stage B = T₃₋₄




Certification assessment after excision of a primary cutaneous melanoma



Comparison of staging classifications for malignant melanoma

Pathological stage	Clinical stage	Tumour thickness	Nodes	Metastases
I	T1	≤1mm	No	No
	T2	1-2mm	No	No
II	T3	2-4mm	No	No
	T4	>4mm	No	No
III	N1	Any	1	No
	N2	Any	2-3	No
	N3	Any	4+	No
IV	M	Any	Yes / No	Yes


Certification assessment after treatment for a germ cell tumour of the testis



International Germ Cell Cancer Collaborative Group (IGCCCG) Prognosis

Good prognosis =	All seminoma except non-pulmonary metastases NSGCT: AFP < 1000 hCG < 5000 LDH < x 1.5 normal	AFP = alphafoetoprotein in ng/ml hCG = human chorionic gonadotrophin in iu/l LDH = lactate dehydrogenase
Intermediate prognosis =	Seminoma with non-pulmonary metastases NSGCT: AFP < 10,000 hCG < 50,000 LDH up to x 10 normal	
Poor prognosis =	NSGCT: AFP > 10,000 hCG > 50,000 LDH more than x 10 normal	

Certification assessment after treatment for renal cell carcinoma



*UCLA = University of California Los Angeles

UCLA integrated staging system for N₀M₀ renal cell carcinoma

Risk factor	T stage	Grade	Performance status	5 year survival
Low	1	1-2	0	91%
Intermediate	1, 2 or 3	Any	Any	71-80%
High	4	Any	0	40-55%
	or 3	Any	1+	

Performance status is determined according to the Eastern Co-operative Oncology Group criteria.

Certification assessment after treatment for breast cancer

****Guidance material under review****

Certification assessment after treatment for non-small cell lung cancer

